ArticleEndocrinology and metabolism (Seoul, Korea)2026
BRAF Mutation and Tumor Growth Kinetics during Active Surveillance of Papillary Thyroid Microcarcinoma: A Single-Center Retrospective Study.
Article in Endocrinology and metabolism (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgruoundWe investigated tumor volume doubling time (TVDT) during active surveillance of papillary thyroid microcarcinoma (PTMC) and reviewed clinical factors including BRAF mutation associated with tumor progression.
methodsPatients with PTMC who deferred surgery for more than 1 year after diagnosis between 2014 and 2021 and were followed until 2023 were enrolled. Inclusion criteria were papillary thyroid carcinoma confirmed by fine needle aspiration cytology (Bethesda categories V-VI), maximal tumor diameter ≤1 cm, and available BRAF mutation testing.
resultsA total of 85 patients were included. The median age was 49 years, and 63 patients (74%) were female. The positivity rate for BRAF mutation was 51% in the study cohort, and 16 patients (19%) showed rapid-growing disease, defined by a TVDT of less than 5 years. The median follow-up duration was 4.4 years, and 23 patients (27%) underwent surgery after a median of 3.2 years. When TVDT groups were analyzed using logistic regression, sonographic features with microcalcification were associated with tumor growth in binary regression (odds ratio for the group combining slowly and rapid-growing disease was 4.34; 95% confidence interval [CI], 1.41 to 13.35; P=0.010), and BRAF mutation was associated with rapid-growing disease in multinomial regression (odds ratio for rapid-growing disease was 4.48; 95% CI, 1.08 to 18.51; P=0.038).
conclusionBRAF mutation is presumed to be associated with tumor progression and may predict growth of PTMC. Genetic testing including BRAF testing may help distinguishing rapid-growing thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.